In this section:

17 April 2019

Adalimumab (Humira) Biosimilar Survey

We want to understand your experiences of switching from Humira to an adalimumab biosimilar medication - Take our survey here

Towards the end of 2018, the biologic medication Humira (adalimumab) came off patent, paving the way for a number of adalimumab biosimilar medications to be introduced by the NHS. Since that time, a number of you may have been switched from Humira onto one of the available biosimilars (Amgevita, Hulio, Hyrimoz, Imraldi) and we're keen to understand your experiences of switching.

If you're aged 18+ and based in the UK, we'd be really grateful if you could spare a few minutes to take this short survey and tell us about your experiences.

If you currently take Humira and haven't been asked to switch yet, please note that we will keep this survey open for a few months so do feel free to come back to it if you are switched at a later date.

Reporting Side Effects

If you are experiencing side effects with any medication, please do remember that it's important to report suspected side effects using the Yellow Card Scheme. If you'd rather complete a paper form instead, please call 0808 100 3352. 

Do also speak to your dermatologist, rheumatologist or specialist nurse.

The Psoriasis Association is the UK's leading national charity and membership organisation for people affected by psoriasis – patients, families, carers and health professionals Read More >

Get in touch

The Psoriasis Association Dick Coles House 2 Queensbridge Northampton NN4 7BF


Tel :
01604 251 620
WhatsApp :
Registered with Fundraising Regulator -

© The Psoriasis Association Charitable Incorporated Organisation Number: 1180666 Scotland: SC049563 Privacy PolicyCookies

Site by Spoken Image | glitterfish

We use cookies to help us provide you with a better service, but do not track anything that can be used to personally identify you.

If you prefer us not to set these cookies, please visit our Cookie Settings page or continue browsing our site to accept them.